Next Article in Journal
Telecommuting, Off-Time Work, and Intrusive Leadership in Workers’ Well-Being
Next Article in Special Issue
Patient Clothing as a Healing Environment: A Qualitative Interview Study
Previous Article in Journal
Exploring the Role of the Food Environment in Dietary Acculturation: A Study amongst Moroccan Immigrants in The Netherlands
Previous Article in Special Issue
Problems and Implications of Shelter Planning Focusing on Habitability: A Case Study of a Temporary Disaster Shelter after the Pohang Earthquake in South Korea
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 18
Issue 7
10.3390/ijerph18073329
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Neurophysiological Approach by Self-Control of Your Stress-Related Autonomic Nervous System with Depression, Stress and Anxiety Patients

by
Kees Blase
1,*,
Eric Vermetten
2,
Paul Lehrer
3 and
Richard Gevirtz
4
1
National Centre Stress Management, Innovational and Educational Centre HartFocus, 1231 NC78 Loosdrecht, The Netherlands
2
Department Psychiatry, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
3
Rutgers Medical School, Rutgers University, Monmouth Junction, NJ 08852, USA
4
California School of Professional Psychology, Alliant International University, San Diego, CA 92131, USA
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(7), 3329; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073329
Submission received: 22 January 2021 / Revised: 23 February 2021 / Accepted: 8 March 2021 / Published: 24 March 2021
(This article belongs to the Special Issue Towards a Public Health Wellness: Psychosocial & Physical Health in Community)
Browse Figures
Versions Notes

Abstract

:
Background: Heart Rate Variability Biofeedback (HRVB) is a treatment in which patients learn self-regulation of a physiological dysregulated vagal nerve function. While the therapeutic approach of HRVB is promising for a variety of disorders, it has not yet been regularly offered in a mental health treatment setting. Aim: To provide a systematic review about the efficacy of HRV-Biofeedback in treatment of anxiety, depression, and stress related disorders. Method: Systematic review in PubMed and Web of Science in 2020 with terms HRV, biofeedback, Post-Traumatic Stress Disorder (PTSD), depression, panic disorder, and anxiety disorder. Selection, critical appraisal, and description of the Random Controlled Trials (RCT) studies. Combined with recent meta-analyses. Results: The search resulted in a total of 881 studies. After critical appraisal, nine RCTs have been selected as well as two other relevant studies. The RCTs with control groups treatment as usual, muscle relaxation training and a “placebo“-biofeedback instrument revealed significant clinical efficacy and better results compared with control conditions, mostly significant. In the depression studies average reduction at the Beck Depression Inventory (BDI) scale was 64% (HRVB plus Treatment as Usual (TAU) versus 25% (control group with TAU) and 30% reduction (HRVB) at the PSQ scale versus 7% (control group with TAU). In the PTSD studies average reduction at the BDI-scale was 53% (HRV plus TAU) versus 24% (control group with TAU) and 22% (HRVB) versus 10% (TAU) with the PTSD Checklist (PCL). In other systematic reviews significant effects have been shown for HRV-Biofeedback in treatment of asthma, coronary artery disease, sleeping disorders, postpartum depression and stress and anxiety. Conclusion: This systematic review shows significant improvement of the non-invasive HRVB training in stress related disorders like PTSD, depression, and panic disorder, in particular when combined with cognitive behavioral therapy or different TAU. Effects were visible after four weeks of training, but clinical practice in a longer daily self-treatment of eight weeks is more promising. More research to integrate HRVB in treatment of stress related disorders in psychiatry is warranted, as well as research focused on the neurophysiological mechanisms.

1. Introduction

Heart Rate Variability (HRV) is a neurobiological marker of the autonomic nervous system (ANS) with decreased HRV indices being associated with a variety of negative physical and psychological outcomes [1,2,3,4,5]. Heart Rate Variability Biofeedback (HRVB) is a non-invasive treatment, in which patients are assumed to self-regulate a physiological dysregulated vagal nerve function by restoring the autonomic homeostasis [6,7,8]. This is relevant for stress-related disorders such as sleep disorders, anxiety, asthma, fibromyalgia, recovery of heart failure, and others. In this time of COVID-19 more knowledge about self-control, Digital Health and a balance in the Autonomic Nervous System (ANS) is relevant.
HRVB affects cardiovascular homeostatic reflexes by increasing flexibility and recovery from fight or flight adaptive situations [9]. Thousands of studies have been published about HRV and HRVB. Most of the studies are focused on HRV as marker for instance as predictor of physical outcomes anxiety disorders and PTSD, cancer recovery [10,11,12,13]. HRVB has been characterized as making visible the neurophysiological effect of meditation [14]. Work-related stress develops gradually and effects both the physical and mental health of those experiencing it, which can eventually lead to burnout. Work related stress symptoms include insomnia, sleep disturbances, menstrual disorders, irritation, and depression [2]. HRV represents the ability to adapt to stress and is a marker of physiological stress [1]. Higher HRV amplitude indicates better self-regulation and is associated with lower cardiovascular risk and alleviating symptoms of stress, anxiety [15,16,17]. A recent meta-analysis affirms the efficacy of HRVB with wearable devices on self-reported stress [18].
In this study different HRV-Biofeedback devices are reported like StressEraser, Infinity HRV-Biofeedback and Balance Manager. In this study we will focus on HRV-Biofeedback studies as additional treatment in clinical practice.
In 1996, the Taskforce of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology formulated definitions of the various HRV metrics [1]. These international standards: High Frequency(HF), Very Low Frequency(VLF), and Low Frequency(LF) are derived by spectral analysis of the interbeat interval (RR).
VLF (very low frequency = 0.003–0.04 Hz), when measured over long time frames, has been interpreted as reflecting sympathetic activity (Action); LF (low frequency = 0.04–0.15 Hz) reflects the combination of sympathetic and vagal balance (Balance), though recent studies have questioned this interpretation, and HF (high frequency = 0.15–0.4 Hz) is interpreted as reflecting vagal activity (Calm/sleepy) (see Figure 2).
We can describe this as ABC: Action, Balance, or Calm/Sleepy, where A indicates dominance of VLF (Action in the mind or body)
B indicates Balance between sympathetic and vagal activity or LF, and C indicates dominance of HF (Calm/sleepy) (see Figure 1).
Autonomic Balance is the marker of the state of the ANS. Unconscious perception of safety is reflected in higher HF values, while threat produces HF (vagal) withdrawal and sympathetic activation. Autonomic balance is defined in terms of complex heart rate (HR) patterns that increase and decrease in response to respiratory fluctuations (Figure 2).
However, when clients shift to slow effortless breathing patterns (as shown above), they stimulate reflexes in the Autonomous Nervous System (ANS) and Central Nervous system (CNS) that, over time, “rewire” these systems so as to enhance ANS flexibility. This formula, during slow effortless breathing, LF: (VLF+LF+HF) can be used as an index of the client’s success in achieving their training goals. This formula is used in HRV-Biofeedback instruments Balance Manager and StressEraser Pro. After 20 years of research and clinical work, this formula was maybe more effective than LF:HF.
HRVB is a natural oscillation between the breathing cycle and heartrate. Inhalation temporarily suppresses vagal activity, causing a decrease in the inter-beat interval and an increase in heart rate; exhalation activates vagal activity, causing an increase in the inter-beat interval and a decrease in heart rate [19]. Heart rate is a dynamic function that varies in each moment. An HRV pattern (tachogram) is a composition of three oscillation processes: Respiratory Sinus Arrhythmia (RSA), baroreflex, and vascular rhythm [19].
Until 1996, HRV was primarily used as marker of the autonomic nervous system, but in 1996 Paul Lehrer (in collaboration with Evgeny Vaschillo) reported the observation that if you breath in the frequency of the baroreceptor and you slow down the tertiary oscillator (quietly not moving too much) than the ANS come into autonomic balance.
The body can be brought into the state of autonomic balance through guided breathing with HRV-Biofeedback. Breathing in the resonance frequency (between 0.05 and 0.15 Hz, which is the same as 4–7 breaths per minute) can be compared to guiding someone on a swing by pushing the swing at the correct moment to optimize their swing (resonance). Breathing at resonance frequency trains the reflexes of the cardiovascular system, in particular the baroreflex [19]. Breathing in the resonance frequency (resonance between respiratory and baroreflex rhythms) and using HRV-Biofeedback creates autonomic balance in the ANS and in this study we will show the effects of training Autonomic Balance with HRVB.
Long standing stress, PTSD and traumatic incidents can disturb stability of the Vagus nerve and create complex disturbances in heartbeat, HRV and hyperarousal, allowing overactivation in the Sympathetic Nervous System [6,20,21]. Our nervous system is continuously evaluating risk in the environment through an unconscious process of neuroception [22]. That is why it is innovative and important to integrate neurophysiological body-focused and self-regulating methods like HRVB in treatment of depression, trauma, and anxiety [23,24]. Reduced HRV amplitude has been found in patients with major depression disorder (MDD) [25]. HRV is a biological marker of the autonomic nervous system with decreased HRV indices being associated with MDD patients and probably being a biomarker of depression [26].

2. Method

In 2016, we published a systematic review and we now present an updated systematic review [7]. This review is based on searches in PubMed and Web of Science with an evidence- based critical review based on the GRADE method [27]. GRADE means Grades of Recommendation Assessment, Development and Evaluation. GRADE can be compared to the Prisma Statement with search terms: HRV (and synonyms) combined with PTSD, combat disorder, depression, depressed mood, anxiety, panic disorder (Figure 3).
Studies were screened by title and summary. This produced 881 articles. These articles have been judged by two raters with GRADE criteria, based on relevance (design, validation, setting, period, protocol, scale) and results (starting measures, result, significance, and missing data). The 46 selected articles have been screened again and the 11 selected studies are described in Table 1 in next chapter. Inclusion criteria were HRVB as clinical intervention of depression, PTSD and anxiety disorder with adults. Exclusion criteria: observational studies, anxiety studies with persons without disorders, children, other languages than English and German. Other meta-analyses of HRVB were added to find the evidence-based effects of HRVB treatment.

3. Results

Most studies were single blind studies except for studies of Karavidas and Siepman [35,39]. Double blind study is not possible in biofeedback studies. Al studies had a high validity in presenting starting description and quality of outcome data.

3.1. HRVB as Additional Treatment of Depression

One of the first single blind RCT HRVB studies was focused on 46 female depressed welfare-to-work recipients in California. The HRVB-group (n = 20) and the control group treated by progressive muscle relaxation (n = 26) received antidepressant medicine [30,40].
The HRVB group showed significant reduction in the Beck Depression Inventory (BDI) score from 35.0 (SD 8.0) towards 17, (SD 12.6) in the first 4 weeks and after 8 weeks even towards 7.8. In the control group, reduction was smaller: from 30.1 (SD 10.2) towards 16.9 (SD 13.3) in 8 weeks. Reduction of 78% HRVB, versus 44% in the control group.
Another early RCT study with StressEraser focused on 60 patients after myocard infarct [31]. HRVB was integrated with dialectic behavioral therapy in conjunction with sertraline medication. The control group only used sertraline medication. The reduction on BDI scale was 76% after 12 weeks daily exercising 20 min with HRVB (BDI from 30.9 towards 7.5) versus 29% reduction in control group (BDI from 30.5 towards 22.0).
A third RCT as a bio behavioral intervention for depressive symptoms in patients after cardiac surgery was in Italy [32]. HRVB group and control group, TAU group, received both TAU that consisted of daily counseling sessions such as dietary and smoking cessation counseling, weight management, and stress-management according to the guidelines of the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. The HRVB group added 2 weeks of daily 45 min biofeedback. The significant reduction measured by CES-D (Centre Epidemiological Study-Depression) scale after 2 weeks was 42% compared with the control group’s 1% reduction.
The psychophysiological mechanisms underlying depression as a risk factor for cardiovascular disease, cardiac morbidity, and fatal cardiac events after surgery are still debated. In the Netherlands, a scientific clinical consortium called Benefit is focusing on cardiac rehabilitation and prevention of cardiac diseases using lifestyle interventions and self-regulation programs such as non-smoking programs, personal lifestyle coaching, blended care with eHealth, HRV-Biofeedback, and mindfulness.
Another study in the Netherlands (University of Amsterdam), in cooperation with Paul Lehrer (USA), is a randomized controlled trial with 20 pregnant and 30 non-pregnant women, mean age 31.6 years [33,41]. The intervention consisted of a 5-week HRVB training with weekly 60–90 min sessions and daily exercises with StressEraser. Research has convincingly shown that high levels of maternal stress, anxiety, and depression during pregnancy are not only harmful for the women herself, but may also affect the child she is carrying. The control group was a wait-list group. The Depression Anxiety Stress Scale (DASS) and Pittsburg Sleep Quality Index (PSQI) were administered pre- and post-intervention. Effect sizes were larger in the HRVB group on all scales. The DASS depression scale women started with a score of 5.45 and after 5 weeks went down to 2.8 (reduction 49%). The wait-list reduction was 35%.
In total, two studies of the Kaohsiung Medical University in Taiwan were selected for review: HRVB with heroin users with depressive symptoms and patients with Major Depression Disorder [37,38]. The prevalence of major depressive episodes among heroin users has been found to be 25%. The nine participants had weekly sessions with HRVB software. They had a reduction of 20% on the BDI depression scale, and 25% on the BDI cognitive depression scale.
In 2019, at Kaohsiung Medical University, there was a RCT study with 48 participants with MDD depression and insomnia [38]. The HRVB group received weekly 60-min sessions for 6 weeks, and the control group received medical care only. The significant reduction at the BDI-II scale was 38 versus 1% in the control group. The significant reduction on the sleep disorder scale (PSQI) was 28% in the HRVB group and 5% in the control group. In 2019, at Alliant University in San Diego USA, a dissertation was presented with 37 participants with MDD and a Latino background [36]. There are different factors that appear to limit the access and quality of mental health care for Latinos, including lack of insurance, cultural barriers, stigma, distrust of medical providers, expression of distress, and fear of deportation. The HRVB participants received four HRV-Biofeedback sessions, were trained in diafragmatic breathing and finding their personal resonance frequency. They were provided with an app to be used as a pacer for daily exercising 10–20 min during 4 weeks in addition to sessions with their psychotherapist.
TAU participants completed four consecutive weeks of psychotherapy. Pre- and post-tests show 39.9% reduction in the Patient Health Questionnaire (PHQ-9): from 16.42 (SD2.93) towards 10.85 (SD6.81). With the TAU group reduction was 6.6% from 17.70 (SD 4.61) towards 16.52 (SD 6.57). In the Anxiety test (GAD-7) reduction was 41.3%: from 11.08 (SD3.40) towards 6.50 (SD3.37) versus TAU 8.8% reduction: from 15.36 (SD 4.41) towards 14.00 (SD4.56).

3.2. HRVB as Additional Treatment of PTSD

Although the connection between HRV and PTSD was already well-known the first RCT study of HRVB and PTSD was reported in 2009 [28,42,43,44]. In total, 76 participants were recruited from an urban residential therapeutic community program for the treatment of PTSD with comorbid substance use disorder. After randomization, 38 participants joined the 4 weeks daily program. The HRVB group trained 20 min daily with the StressEraser and the control group received daily 20 min Progressive Muscle Relaxation (PMR). The HRVB group had significantly (p = 0.001) greater reductions in depression scores compared to PMR (Progressive Muscle Relaxation) In HRVB group BDI-II reduced 53% (from 26.4 to 12.3) and 24% (from 25.95 to 19.47). On the scale, 29–63 = severe depression; 20–28 = moderate depression; 14–19 = mild depression; 0–13 = minimal depression. Reduction on PCL scale was 27% (HRVB) compared to 18% (PMR).
A second RCT study, with PTSD and HRVB, was focused on participants of US Department of Veteran Affairs—MEDVAMC [29]. In an 8 weeks program of weekly sessions with the Resonance Frequency protocol of Lehrer et al., veterans were trained in autonomic balance.
PCL score reduced significantly by 16% with HRVB while the TAU control group (only TAU) reduction after 8 weeks was 9% (not significant). Patients reported a satisfaction score of 8 (scale 1–10) and more than 50% wanted to continue using breathing in resonance frequency.
In 2014 a systematic review for psychiatric disorders with integration of treatment with HRVB was published [45]. In 2020, a systematic review and meta-analysis was published showing HRVB improves emotional and physical health, and performance [46]. Their initial review yielded 1868 papers from which 58 met inclusion criteria. HRVB has the largest effect sizes for depression (Hedge g = −0.72 and p < 0.0005), anger (g = −0.54 and p < 0.02), emotion regulation (g = −0.34 and p < 0.0005), asthma (g = −1.357), and athletic performance (g = −90), and smaller effect sizes on PTSD (g = 0.29) and quality of life (g = 0.14). The average effect size of the 58 studies for HRVB and paced breathing versus control conditions was found to be small to medium Hedge g = 0.37. High effect size g = −0.8 medium effect size: g = −0.5 and small effect size: g = −0.2.
In our study, we focalized on Depression, PTSD and Anxiety and with the GRADE method we got a smaller selection of 10 studies. Most of the selected studies showed a large effect size [46]:
[28] PTSD study: g = −0.739
[29] PTSD study: g = −0.296
[30] Depression: g = −0.748
[32] Depression: g = −0.958

4. Discussion

In the first review of RCT studies of Heart Rate Variability Biofeedback the conclusion was: ”a number of research studies have given at least tentative support for the effectiveness of HRVB for a wide range of medical and emotional disorders.”[19].
Below you can see the summary, with addition of the RCT studies after 2014 (Table 2):
While the first studies and RCTs were mostly done in USA, you can see the emergence of high quality studies from all over the world (Germany, the Netherlands, Belgium and the UK, South Korea, Taiwan, Japan, Brazil, and Australia).
In our manuscript the systematic review is focused on depression, PTSD, and anxiety. Effects were visible after 4 weeks of HRVB-training, but clinical practice in a longer daily self-treatment of 8 weeks showed more reduction on the BDI. Daily HRV-Biofeedback was more effective than weekly training, as we see in the studies of Rene and Chaudri with the StressEraser [31,40]. Perhaps three 8 min a day or two 10 min a day sessions are the most effective7.
Interestingly, in the systematic review it was stated: “an interesting implication of our findings is that length of treatment and home practice does not influence the effect size. Perhaps learning how to breathe at resonance frequency provides a sufficient method for most of the beneficial effects.”(p. 125) [46].
The StressEraser, used in many of the HRVB studies was a noninvasive portable handheld device attempting to increase RSA using a respiratory training system. A highly sensitive infrared light sensor detects tiny changes in the rate at which blood pulses through the fingertip. The finger sensor has a photoplethysmograph to identify every pulse. The StressEraser (Figure 4a) was a very effective device, because the resonance frequency (resonance between heart rhythm and breathing rhythm) was automatically seen on the screen. StressEraser is not any more available since 2015. However, the StressEraser Pro (Figure 4b) has been developed for iPhone with more detailed information of HRV patterns:
In this StressEraser Pro, you can read the tachogram, the frequency spectre with VLF (Orange), LF (purple), and HF (green) and the training effect score: LF/(VLF+ LF + HF).
For Samsung phones the HRV biofeedback device ResCalm (Figure 5) has been developed in South Korea with 10 playful wave patterns like hills, mountains, and motivating wave movements. Data definition is the same as the Balance Manager (Figure 6) for Windows computer.
Additionally, in the Infinity HRV biofeedback devices (Figure 7), playful pictures are effective in the treatment.
All these devices were very effective, because users can install their personal frequency and their preferred rate of inhalation–exhalation. While searching for different systematic reviews, we also found a study that used HRV-Biofeedback devices that only used the frequency of 0.1 Hz [63]. That study did not show significant results compared with the devices where a client can install a personal breathing frequency like Balance Manager, StressEraser Pro, and Infinity.
In spite of the significance and efficacy of HRVB showed in this systematic review HRVB is not yet integrated into standard treatment. One of the most popular therapies is Acceptance and Commitment Therapy (ACT) [64]. In most trials ACT is reported to be superior or equally effective as cognitive behavioral therapy [65].Maybe it would be more efficient for our health system to integrate psychophysiology like ACT, HRV-Biofeedback and mindfulness in treatment of depression, PTSD, and anxiety disorders, because of the efficacy, more self-control of the client, and lowering the cost of treatment [66].

Limitations

The search strategy was bias-free but limited to articles published in English.

5. Conclusions

More than 4000 studies that investigated HRV, show the relevance of HRV in neuroscience related to a range of medical and emotional disorders and especially stress related disorders. Stress related disorders have a connection to a disturbance of the Autonomic Nervous System and a dysregulated Vagus nerve.
This systematic review shows significant improvement of the non-invasive HRVB training in stress related disorders like PTSD, depression and panic disorder, in particular when combined with cognitive behavioral therapy or other TAU.
After critical appraisal from the 881 studies about depression, PTSD and anxiety, eight RCT studies and two related studies have been selected. The RCTs with control groups treatment as usual combined with muscle relaxation training, and a “placebo“-biofeedback instrument revealed significant clinical efficacy and better results compared with control conditions, mostly significant (p < 0.001).
In the depression studies average reduction at the Beck Depression Inventory scale was 64% (HRVB plus TAU) versus 25% (control group with TAU) and 30% reduction (HRVB) at the PSQ scale versus 7% (control group with TAU).
In the PTSD studies average reduction at the BDI scale was 53% (HRVB plus TAU) versus 24% (control group with TAU) and 22% (HRVB) versus 10% (TAU) with the PCL scale. Even with studies with groups from 26 to 60 participants there is significance efficacy, so the effect size is very interesting.
In the different meta-analyses, significant effects have been shown of HRVB in treatment of asthma, angina pectoris, coronary artery disease, sleeping disorders, prevention of postpartum depression, and stress and anxiety.
More research on the integration of HRVB in the treatment of stress related disorders in psychiatry is warranted. In addition, research focused on the neurophysiological mechanisms will solidify the scientific basis of HRVB.
Nevertheless, because financial support for behavioral research has not reached the level necessary to test thousands of, meta-analysis may be the best alternative for evaluating these effects.

Author Contributions

Conceptualization, K.B., E.V. and R.G.; formal analysis, K.B. and E.V.; resources, K.B., P.L. and R.G.; writing—original draft preparation, K.B.; writing—review and editing, E.V., R.G. and P.L.; project administration, K.B.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Taskforce of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability, Standards of measurement, physiological interpretation and clinical use. Eur. Heart J. 1996, 17, 354–381. [Google Scholar] [CrossRef] [Green Version]
  2. Lin, I.M.; Fan, S.Y.; Lu, H.C.; Lin, T.H.; Chu, C.S.; Kuo, H.F.; Lee, C.S.; Lu, Y.H. Randomized contolled trial of heart rate variability biofeedback in cardiac autonomic and hostility among patients with coronary artery disease. Behav. Res. Ther. 2015, 70, 38–46. [Google Scholar] [CrossRef]
  3. Agelink, M.; Boz, C.; Ullrich, J. Relationship between major depressive disorder and heart rate variability. Clinical consequences and implications for antidepressive treatment. Psychiatry Res. 2002, 113, 139–149. [Google Scholar] [CrossRef]
  4. Berntson, G.G.; Bigger, J.T.; Eckberg, D.L.; Grossman, P. HRV: Origins, methods and interpretive caveats. J. Psychophysiol. 1997, 34, 623–648. [Google Scholar] [CrossRef] [PubMed]
  5. Gevirtz, R.; Lehrer, P. Resonance frequency heart rate feedback. In Biofeedback, a Practitioner’s Guide, 3rd ed.; Schwartz, M.S., Andrasik, F., Eds.; Guilford: New York, NY, USA, 2003; pp. 245–264. [Google Scholar]
  6. Porges, S.W. The Polyvagal Theory; Neuropsychological Foundations of Emotions, Attachment, Communication and Selfregulation; Norton: New York, NY, USA; London, UK, 2011. [Google Scholar]
  7. Blase, K.; van Dijke, A.; Cluitmans, P.; Vermetten, E. Effectiviteit van hartritme variabiliteit biofeedback als aanvulling bij behandeling van depressie en posttraumatische stressstoornis. Tijdschr. Voor Psychiatr. 2016, 4, 293–300. [Google Scholar]
  8. Gevirtz, R. Autonomic nervous system markers for psychophysiological, anxiety and physical disorders. Integr. Neurosci. Pers. Med. 2010, 164–180. [Google Scholar]
  9. Gevirtz, R. The promise of Heart Rate Variability Biofeedback: Evidence-based application. Biofeedback 2013, 41, 110–120. [Google Scholar] [CrossRef] [Green Version]
  10. Sloan, R.; Shapiro, P.A.; Gorenstein, E.E.; Tager, F.A.; Monk, C.E.; McKinley, P.S.; Myers, M.M.; Bagiella, E.; Chen, I.; Steinman, R.; et al. Cardiac autonomic control and treatment of hostility: A randomized contolled trial. Psychosom. Med. 2010, 72, 1–8. [Google Scholar] [CrossRef] [Green Version]
  11. Lin, S.L.; Huang, C.Y.; Shiu, S.P.; Yeh, S.H. Effects of yoga on stress, stress adaptation and Heart Rate Variability among mental health professionals. Worldviews Evid. Based Nurs. 2015, 12, 236–245. [Google Scholar] [CrossRef]
  12. Chalmers, J.A.; Quintana, D.S.; Abbott, M.J.; Kemp, A.H. Anxiety disorders are associated with reduced heart rate variability. Front. Psychiatry 2014, 5, 80. [Google Scholar] [CrossRef] [Green Version]
  13. Larkey, L.; Kim, W.; James, D. Mind-body and psychosocial interventions may similarly affect Heart Rate Variability patterns in cancer recovery. Integr. Cancer Ther. 2019, 19, 1–10. [Google Scholar]
  14. Blase, K.; van Waning, A. Heart Rate Variability, cortisol and attention focus during Shamatha quiescence meditation. Appl. Psychophysiol. Biofeedback 2019, 44, 331–342. [Google Scholar] [CrossRef]
  15. Kiviniemi, A.M.; Hautala, A.J.; Kinnunen, H.; Nissilä, J.; Virtanen, P.; Karjalainen, J.; Tulppo, M.P. Daily exercise prescription on the basis of HRV among men and women (Randomied Controlled Trial). Med. Sci. Sports Exerc. 2010, 42, 1355–1363. [Google Scholar] [CrossRef]
  16. Prinsloo, G.; Derman, W.; Lambert, M.; Rauch, H. The effect of a single session of short duration biofeedback induced deep breathing on measures of HRV during laboratory induced cognitive stress. Appl. Psychophysiol. Biofeedback 2013, 38, 81–90. [Google Scholar] [CrossRef]
  17. Lewis, G.; Hourani, L.; Tueller, S.; Weimer, B. Relaxation training assisted by HRVB: Implication for a military predeployment stress inoculation protocol. Psychophysiology 2015, 52, 1167–1174. [Google Scholar] [CrossRef]
  18. Goessl, V.; Curtiss, J.; Hofmann, S. The effect of HRV biofeedback training on stress and anxiety: A meta-analysis. Psychol. Med. 2017, 47, 2578–2586. [Google Scholar] [CrossRef]
  19. Lehrer, P.; Gevirtz, R. Heart Rate Variability biofeedback: How and why does it work? Front. Psychol. 2014, 5, 756. [Google Scholar] [CrossRef] [Green Version]
  20. Carney, R.M.; Freedland, K.E.; Skala, E.A.; Jaffe, A.S. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med. 2000, 62, 639–647. [Google Scholar] [CrossRef] [PubMed]
  21. Cohen, H.J.; Benjamin, J.; Matar, M.A.; Kaplan, Z. Autonomic dysregulation in panic disorder and in posttraumatic stress disorder: Application of power spectrum analysis of heart rate variability at rest and in response to recollection of trauma or attacks. Psychiatry Res. 2000, 96, 1–13. [Google Scholar] [CrossRef]
  22. Porges, S.W.; Dana, D.A. Clinical Applications of the Polyvagal Theory: The Emergence of Polyvagal-Informed Therapies; Norton Series on Interpersonal Neurobiology; WW Norton & Company: New York, NY, USA, 2018. [Google Scholar]
  23. Van der Kolk, B. Clinical Implications of Neuroscience Research in PTSD. Psychobiology of Posttraumatic Stress Disorders; Annals of the New York Academy of Sciences; Blackwell Publishing: Oxford, UK, 2006; Volume 1071, pp. 277–293. [Google Scholar]
  24. Lanius, R.; Vermetten, E.; Pain, C. The Hidden Epidemic; the Impact of Early Life Trauma on Health and Disease; Cambridge University Press: Cambridge, UK, 2010. [Google Scholar]
  25. Licht, C.; de Geus, E.; Zitman, F.; Hoogendijk, W.; van Dijck Penninx, B. Association between major depression disorder and HRV in the Netherlands Study of Depression and Anxiety (NESDA). Arch. Gen. Psychiatry 2008, 65, 1358–1367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Sgoifo, A.; Carnevali, I.; Alfonso, M.; Amore, M. Autonomic dysfunction and heart rate variability in depression. Stress 2015, 18, 343–352. [Google Scholar] [CrossRef]
  27. GRADE Working Group. Grading quality of evidence and strength of recommandations. BMJ 2004, 328, 1490. [Google Scholar] [CrossRef] [Green Version]
  28. Zucker, T.L.; Samuelson, K.W.; Muench, F.; Gevirtz, R.N. The effects of respiratory sinus arrhythmia biofeedback on heart rate variability and posttraumatic stress disorder symptoms. Appl. Psychophysiol. Biofeedback 2009, 34, 135–143. [Google Scholar] [CrossRef]
  29. Tan, G.; Dao, T.K.; Farmer, L.; Sutherland, R.J.; Gevirtz, R. Heart Rate Variability and Posttraumatic Stress Disorder: A pilot study. Appl. Psychophysiol. Biofeedback 2011, 36, 27–35. [Google Scholar] [CrossRef] [PubMed]
  30. Rene, R. The efficacy of a portable HRV feedback device in conjunction with mental health treatment of clients with major depressive disorder enrolled in a country welfare-to-work program. Diss. Abstr. Int. Sect. B Sci. Eng. 2008, 69, 2000. [Google Scholar]
  31. Chaudhri, P. The Effects of Cardiorespiratory Biofeedback and Dialectical Behavioral Skills Training with Sertraline on Post Myocardial Infarction Major Depression and Low Heart Rate Variability; Alliant University: San Diego, CA, USA, 2008. [Google Scholar]
  32. Patron, E.; Benvenutti, G.F.; Palomba, D. Biofeedback assisted control of RSA as a biobehavioral intervention for depressive symptoms in patients after cardiac surgery: A preliminary study. Appl. Psychophysiol. Biof. 2013, 38, 1–9. [Google Scholar] [CrossRef] [PubMed]
  33. Van der Zwan, J.; Huizink, A.; Lehrer, P.; Koot, H.; Vente, W. The effect of Heart Rate Variability Biofeedback training on mental health of pregnant and non-pregnant women: A randomized contolled trial. Int. J. Environ. Res. Public Health 2019, 16, 1051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Karavidas, M.; Lehrer, P.; Vaschillo, E.; Vaschillo, B.; Marin, H.; Buyske, S. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. Appl. Psychophysiol. Biofeedback 2007, 32, 19–30. [Google Scholar] [CrossRef] [PubMed]
  35. Siepman, M.; Aykac, V.; Unterdorfer, J.; Mueck-Weymann, M. A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects. Appl. Psychophysiol. Biofeedback 2008, 33, 195–201. [Google Scholar] [CrossRef] [PubMed]
  36. Thode, L. Heart Rate Variability Biofeedback as a Complementary Treatment for Depression in Latinos; Alliant International University: San Diego, CA, USA, 2019. [Google Scholar]
  37. Lin, I.M.; Ko, J.M.; Fan, S.Y.; Yen, C.F. Heart Rate Variability and the efficacy of biofeedback in heroin users with depressive symptoms. Clin. Psychopharmacol. Neurosci. 2016, 14, 168–176. [Google Scholar] [CrossRef] [Green Version]
  38. Lin, I.M.; Fan, S.Y.; Yen, C.F.; Yeh, Y.C.; Tang, T.C.; Huang, M.F.; Liu, T.L.; Wang, P.W.; Lin, H.C.; Tsai, H.Y.; et al. Heart Rate Variability biofeedback increased autonomic activation and improved symptoms of depression and insomnia among patients with Major Depression Disorder. Clin. Psychopharmacol. Neurosci. 2019, 17, 222–232. [Google Scholar] [CrossRef]
  39. Karavidas, M.K. Heartrate variability biofeedback for major depression. Biofeedback 2008, 36, 18–21. [Google Scholar]
  40. Rene, R. The Efficacy of a Portable Heart Rate Variability Feedback Device in Conjunction with Mental Health Treatment of Clients with Major Depressive Disorder Enrolled in a County Welfare-to-Work Program; Alliant University: San Diego, CA, USA, 2011. [Google Scholar]
  41. De Bruin, E.; Van der Zwan, J.; Bogels, S. A RCT Compairing Daily Mindfulness meditations, Biofeedback Exercises and Physical Exercise on Attention Control, Executive Functioning, Mindful Awareness, SelfCompassion and Worrying in Stressed Young Adults. Mindfullness 2016, 7, 1182–1192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Porges, S. Respiratory sinus arrhythmia: Physiological basis, quantitative methods and clinical implications. In Cardiorespiratory and Cardiosomatic Psychophysiology; Plenum Press: New York, NY, USA, 1986; pp. 101–115. [Google Scholar]
  43. Blanchard, E. Elevated basal level of cardiovascular responses in Vietnam veterans with PTSD: a health problem I the making? J. Anxiety Disord. 1990, 4, 233–237. [Google Scholar] [CrossRef]
  44. Cohen, H.; Kotler, M.; Matar, M.; Kaplan, Z. Power spectral analysis of heart rate variability in posttraumatic stress disorder patients. Biol. Psychiatry 1997, 41, 627–629. [Google Scholar] [CrossRef]
  45. Schoenberg, P.L.; David, A.S. Biofeedback for psychiatric disorders: A systematic review. Appl. Psychophysiol. Biofeedback 2014, 39, 109–135. [Google Scholar] [CrossRef]
  46. Lehrer, P.; Kaur, K.; Sharma, A.; Shah, K.; Huseby, R.; Bhavsar, J.; Zhang, Y. Heart Rate Variability Biofeedback Improves Emotional and Physical Health and Performance: A Systematic Review and Meta Analysis. Appl. Psychophysiol. Biofeedback 2020, 45, 109–129. [Google Scholar] [CrossRef] [PubMed]
  47. Lehrer, P.; Vaschillo, E.; Vaschillo, B.; Habib, H. Biofeedback treatment for asthma. Chest 2004, 126, 352–361. [Google Scholar] [CrossRef] [Green Version]
  48. Nolan, R.P.; Kamath, M.V.; Floras, J.S.; Picton, P. Heart Rate Variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control. Am. Heart J. 2005, 149, 1137.e1–1137.e7. [Google Scholar] [CrossRef] [PubMed]
  49. Lee, J.; Kim, J.; Wachholtz, A. The benefit of heart rate variability biofeedback and relaxation training in reduction trait anxiety. Hanguk Simni Hakhoe Chi. Kongang 2015, 20, 391–408. [Google Scholar]
  50. Henriques, G.; Keffer, S.; Abrahamson, C.; Horst, S.J. Exploring the effectiveness of a computer-based HRV biofeedback program in reducing anxiety in college students. Appl. Psychophysiol. Biofeedback 2011, 36, 101–112. [Google Scholar] [CrossRef]
  51. De Couck, M.; de Leeuw, I.; Blase, K.; Gidron, Y. Effects of heart rate variability biofeedback on the tumor marker CEA in metastatic colon cancer. J. Immunol. Res. 2018, 79, A18. [Google Scholar]
  52. Windthorst, P.; Mazurak, N.; Kuske, M.; Hipp, A.; Giel, K.E.; Enck, P.; Nieß, A.; Zipfel, S.; Teufel, M. Heart Rate Variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome. J. Psychosom. Res. 2017, 93, 6–13. [Google Scholar] [CrossRef]
  53. Berry, M.; Ginsberg, J.; Nagpal, M. Non-pharmalogical intervention for chronic pain in veterans: A pilot study of HRV. Glob. Adv. Health Med. 2014, 3, 28–33. [Google Scholar] [PubMed] [Green Version]
  54. Del Pozo, J.M.; Gevirtz, R.N.; Scher, B.; Guarneri, E. Biofeedback treatment increases heart rate variability in patients with known coronary artery disease. Am. Heart J. 2004, 147, 545. [Google Scholar] [CrossRef]
  55. Yu, L.C.; Lin, I.M.; Fan, S.Y.; Chien, C.L.; Lin, T.H. One year cardiovascular prognosis of the randomized controlled short term HRV biofeedback among patients with coronary artery disease. Int. J. Behav. Med. 2018, 25, 271–282. [Google Scholar]
  56. Francis, H.; Penglis, K.; Mc Donald, S. Manipulation of heart rate variability can modify response to anger-inducing stimuli. Soc. Neurosci. 2016, 11, 545–552. [Google Scholar] [CrossRef]
  57. Sequeira, V.; Bandeira, P.; Azevedo, J. Heart Rate Variability in adults with obstructive sleep apnea: A systematic review. Sleep Sci. 2019, 12, 214–221. [Google Scholar] [CrossRef] [PubMed]
  58. Hasuo, H.; Kanbara, K.; Fukunaga, M. Effect of Heart Rate Variability biofeedback sessions with resonant breathing on sleep. Sci. Rep. 2020, 10, 7427. [Google Scholar]
  59. Clamor, A.; Koenig, J.; Thayer, J.; Lincoln, T. A randomized-controlled trial of heart rate variability for psychotic symptoms. Behav. Res. 2016, 87, 207–215. [Google Scholar] [CrossRef]
  60. Van der Zwan, J.; de Vente, W.; Huizink, A.; Bögels, S.; de Bruin, E. Physical activity, mindfulness meditation, or HRVbiofeedback for stress reduction: a randomized contolled trial. Appl. Psychophysiol Biofeedback 2015, 40, 257–268. [Google Scholar] [CrossRef] [Green Version]
  61. Stern, M.; Guilles, R.; Gevirtz, R. HRVBiofeedback for Pedriatic Irritable Bowel Syndrome and Functional Abdominal Pain: a clinical replication series. Appl. Psychophysiol. Biofeedback 2014, 39, 3–4. [Google Scholar] [CrossRef] [PubMed]
  62. Kudo, N.; Shinohara, H.; Kodama, H. Heart Rate Variability biofeedback intervention for reduction of psychological stress during the early postpartum period. Appl. Psychophysiol. Biofeedback 2014, 39, 203–211. [Google Scholar] [CrossRef] [Green Version]
  63. Lande, R.G.; Williams, L.B.; Marin, M.L. Efficacy of biofeedback for post-traumatic stress disorder. Complement. Med. 2010, 18, 256–259. [Google Scholar] [CrossRef] [PubMed]
  64. Hayes, S.; Strosahl, K.; Wilson, K. Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change; Guilford Press: New York, NY, USA, 1999. [Google Scholar]
  65. Gevirtz, R. Incorporating HRV biofeedback info Acceptance and Commitment Therapy. Biofeedback 2020, 48, 16–19. [Google Scholar] [CrossRef]
  66. Brinkman, A.; Press, S.; Helmert, E.; Hautzinger, M.; Khazan, I.; Vagedes, J. Comparing effectiveness of HRVB and mindfulness for workplace stressreduction: A Randomized controlled trial. Appl. Psychophysiol. Biofeedback 2020, 45, 307–322. [Google Scholar] [CrossRef]
Ijerph 18 03329 g001 550
Figure 1. HRV (Heart Rate Variability) patterns (tachogram).
Figure 1. HRV (Heart Rate Variability) patterns (tachogram).
Ijerph 18 03329 g001
Ijerph 18 03329 g002 550
Figure 2. HRV as composition of 3 oscillation processes [7]
Figure 2. HRV as composition of 3 oscillation processes [7]
Ijerph 18 03329 g002
Ijerph 18 03329 g003 550
Figure 3. Flow diagram (for the selection of review articles).
Figure 3. Flow diagram (for the selection of review articles).
Ijerph 18 03329 g003
Ijerph 18 03329 g004 550
Figure 4. (a) StressEraser. (b) StressEraser Pro.
Figure 4. (a) StressEraser. (b) StressEraser Pro.
Ijerph 18 03329 g004
Ijerph 18 03329 g005 550
Figure 5. ResCalm.
Figure 5. ResCalm.
Ijerph 18 03329 g005
Ijerph 18 03329 g006 550
Figure 6. Balance Manager.
Figure 6. Balance Manager.
Ijerph 18 03329 g006
Ijerph 18 03329 g007 550
Figure 7. Infinity biofeedback.
Figure 7. Infinity biofeedback.
Ijerph 18 03329 g007
Table
Table 1. The results of the selected studies.
Table 1. The results of the selected studies.
RCT Studies HRVB for Treatment PTSD and Depression
RELEVANCERESULTS
AutorDesignnDomainSettingPeriodScalePrePostReductionSignif.
RCT/SGT ExpExpExpContPre-Post
Zucker (2009)[28]RCT
HRVB vs. PMR		38PTSD1e line4 weeks dailyPCL52.638.627%18%p < 0.05
BDI-II26.412.353%24%p < 0.05
Tan (2011) [29]RCT
HRVB vs. TAU		20PTSDVeteran hosp8 weeks dailyPCL-S64.854.416%2%p < 0.05
CAPS86.471.218%9%p < 0.001
Rene (2008) [30]RCT
HRVB vs. PMR		46Depression1e line8 weeks dailyBDI-II35.07.878%44%p < 0.005
Chaudhri (2008) [31] RCT HRVB+DBT
vs sertraline		60Depressionuniv.hos12 weeks dailyBDI-II31.07.576%29%p < 0.001
DERS123.164.248%8%p < 0.001
Patron (2013) [32]RCT
HRVB vs. TAU		26Depression
after infarct		univ.hos2 weeks
daily		CES-D15.38.942%1%p = 0.02
Van der Zwan (2019) [33]RCT
HRVB vs. waitinglist		50Depression Anxiety
Stress		University pregnant
Women		5 weeks dailyDASS PSQI5.45
6.55		2.
84.7		49%
21%		35%
10%		p = 0.039 p = 0.063
Karavidas (2007) [34]SGT11Depressionuniv.hos10 weeksBDI26.012.552%-p < 0.001
Siepman (2008) [35]HRVB
vs. healthy		38Depressionuniv.h vs. stud4 weeks 3× a
Week		BDI21.55.574%-p < 0.05
Thode (2019) [36]RCT HRVB
vs. TAU		37MDDLatinoHealth
center		4 weeksPHQ-9
GAD-7		16.42
11.08		10.85
6.50		40%
41%		7%
9%		p <0.05
p < 0.05
Lin (2016)[37]Case control study9MDD
Depression		Heroin users5weeks
1× a week		BDI-II
BDI cogn		23
19		18.3
14.3		20%
25%		-p > 0.05
Lin (2019) [38]RCT
HRVB vs. med.care		48MDD3 hospitals6 weeksBDI-II PSQI24.25
12.42		15.04
8.92		38%
28%		1%
5%		p = 0.007 p = 0.012
RCT: Randomized controlled trial; SGT: Single Group Trial; PMR = progressive muscle relaxation; DBT = dialectical behavioral therapy; PPD: postpartum depression; univ.hos = university hospital; BDI: Beck Depression Inventory; PCL: PTSD Check-List; CAPS: Clinical Administered PTSD Scale; CES-D: Centre Epidemiological Study-Depression; DERS: Difficulty in Emotion Regulation Scale; STAI: State-Trait Anxiety Inventory; PHQ-9: Patient Health Questionnaire; GAD-7: Generalized Anxiety Disorder.
Table
Table 2. Search HRVB RCT studies.
Table 2. Search HRVB RCT studies.
Asthma [47]n = 64p < 0.003USA
Angina Pectoris [48]n = 63p < 0.001Canada
Angina Pectoris [11]n = 154sigTaiwan
Anxiety [49]n = 15sigSouth Korea
Anxiety [50]n = 40p < 0.05USA
Cancer [51]n = 5p < 0.06Belgium
Chronic fatigue syndrome [52]n = 28sigGermany
Chronic Pain [53]n = 20p < 0.001USA
Coronary artery disease [54]n = 63p < 0.001USA
Coronary artery disease [55]n = 210p = 0.001Taiwan
Depression (see Table 1)n = 230sigUSA, Italy, Taiwan, Netherlands
Emotion regulation [56]n = 58sigAustralia
Sleep apnea [57]n = 853sigBrazil
Sleep [58]n = 69p = 0.001Japan
Selfcontrol Psychotic sympt [59]n = 84p = 0.006Germany
Stress and anxiety [18]n = 484Hedges g = 0.81USA
Stressreduction [60]n = 23sigNetherlands
Pediatric Irritable Bowel Syndr [61] n = 24sigUSA
Postpartum depression [62]n = 55p < 0.001Japan
PTSD (see Table 1)n = 97p < 0.05USA
Trait Anxiety [49]n = 15sigSouth Korea
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Blase, K.; Vermetten, E.; Lehrer, P.; Gevirtz, R. Neurophysiological Approach by Self-Control of Your Stress-Related Autonomic Nervous System with Depression, Stress and Anxiety Patients. Int. J. Environ. Res. Public Health 2021, 18, 3329. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073329

AMA Style

Blase K, Vermetten E, Lehrer P, Gevirtz R. Neurophysiological Approach by Self-Control of Your Stress-Related Autonomic Nervous System with Depression, Stress and Anxiety Patients. International Journal of Environmental Research and Public Health. 2021; 18(7):3329. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073329

Chicago/Turabian Style

Blase, Kees, Eric Vermetten, Paul Lehrer, and Richard Gevirtz. 2021. "Neurophysiological Approach by Self-Control of Your Stress-Related Autonomic Nervous System with Depression, Stress and Anxiety Patients" International Journal of Environmental Research and Public Health 18, no. 7: 3329. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18073329

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop